Wyeth Pharmaceuticals signed a definitive agreement to acquire Haptogen Ltd., a Scottish biopharmaceutical company based in Aberdeen. Haptogen will become part of Wyeth Discovery Research. Haptogen has developed technologies that allow for the discovery and optimization of protein therapeutics with improved profiles over the current generation of protein therapies. The benefits include the potential for more convenient routes of administration as well as cell and organ penetration, addressi...